Therapies for the treatment of rare pulmonary diseases

Kither Biotech is focused on developing innovative therapies for rare respiratory diseases, particularly cystic fibrosis (CF) and idiopathic pulmonary fibrosis (IPF). The company has created two key drug candidates: KIT2014, a small peptide that acts as a cAMP modulator, and KITCL27, a small molecule PI3K inhibitor. KIT2014 has received orphan drug designation from the European Medicines Agency and works by enhancing cAMP responses within cells, which is crucial for addressing the dysfunctional CFTR protein responsible for cystic fibrosis. Meanwhile, KITCL27 is designed to inhibit the PI3K signaling pathway, which is implicated in excessive fibroblast growth in IPF, thereby potentially reducing lung scarring and improving pulmonary function.

The unique pharmacological profiles of these compounds allow for targeted treatment with minimized systemic side effects. KITCL27, for instance, is formulated as a prodrug suitable for inhalation, ensuring that its activity is localized to the lungs and does not affect other tissues, such as blood glucose levels. This localized approach not only enhances the therapeutic efficacy but also reduces the risk of adverse effects commonly associated with systemic PI3K inhibitors. Kither Biotech's commitment to addressing high unmet medical needs in respiratory diseases is evident in its strategic focus on these innovative signal transduction modulators.

Italy

Kither Biotech is a biopharmaceutical company that develops novel therapies for the treatment of rare pulmonary diseases with an high unmet medical need. Our first two product candidates KIT2014 and KITCL27, focus on cystic fibrosis and idiopathic pulmonary fibrosis respectively.

Kither Biotech

Company Details